Study of Darifenacin in Patients Suffering From Multiple Sclerosis and Neurogenic Detrusor Overactivity

This study has been terminated.
(The enrollment rate at most centers was unlikely to result in the recruitment of the planned sample size of 40 evaluable subjects.)
Sponsor:
Information provided by (Responsible Party):
Bayer
ClinicalTrials.gov Identifier:
NCT00845338
First received: February 16, 2009
Last updated: November 28, 2014
Last verified: November 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: October 2007
  Primary Completion Date: October 2007 (Final data collection date for primary outcome measure)